Psoriasis patients treated with methotrexate are almost three times more likely to develop nonmelanoma skin cancer.

At the American Academy of Dermatology (AAD) annual meeting in New Orleans, research findings that showed systemic treatment of psoriasis...

Psoriasis patients reported that application feel, non-staining quality and quick absorption were important in topical treatments

A U.S. study has found that less than half of psoriasis patients report frequently engaging in shared decision-making with their...

Guselkumab does not increase cancer risk in psoriasis patients compared to general and psoriasis populations.

Risankizumab has been shown to be efficacious and safe in patients with plaque psoriasis who have a suboptimal response to IL-17 inhibitors.

There is no increased risk of infections in pediatric psoriasis patients treated with ustekinumab compared to etanercept or methotrexate.

Psoriasis patients are significantly more likely to experience migraines than those without psoriasis.